Shopping Cart

Your shopping cart is currently empty

Zunsemetinib

Name: Zunsemetinib
Brand: TargetMol
SKU: T39126
Price: 66 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T39126Cas No. 1640282-42-3

Alias CDD-450, ATI-450

Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.Zunsemetinib is used to study spondyloarthritis and rheumatoid arthritis.

Zunsemetinib

Copy Product Info

😃Good

Purity: 99.77%

Catalog No. T39126Alias CDD-450, ATI-450Cas No. 1640282-42-3

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$66	In Stock	In Stock
5 mg	$158	-	In Stock
10 mg	$248	-	In Stock
25 mg	$397	-	In Stock
1 mL x 10 mM (in DMSO)	$179	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.77%

Appearance:Solid

Color:Yellow

Resource Download

COA HPLC HNMR

Product Introduction

Bioactivity

Description	Zunsemetinib (ATI-450) is an orally active and selective inhibitor of the p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway.Zunsemetinib is used to study spondyloarthritis and rheumatoid arthritis.
In vitro	Zunsemetinib selectively blocks p38α MAPK activation of the proinflammatory kinase MK2 while sparing p38α activation of other effectors such as PRAK and ATF2, and inhibits in vitro osteoclast formation induced by RANKL.[1] Zunsemetinib (1 and 10 μM; 1h) decreases IL-1β expression by promoting IL-1β mRNA degradation and has no effect on NLRP3 expression.[1] Zunsemetinib (0.4 nM~1 μM; 16h; PBMC cells) reduces IL-1β secretion and promotes IL-1β mRNA instability.[1]
In vivo	Zunsemetinib (1,000 ppm; p.o.; 8-week-old WT female mice) blocks LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.[1] Zunsemetinib (10 and 20 mg/kg; p.o.) prevents osteopenia in NOM IDc mice through inhibition of osteoclastogenesis and increases bone density.[1]
Synonyms	CDD-450, ATI-450

Chemical Properties

Molecular Weight	513.92
Formula	C₂₅H₂₂ClF₂N₅O₃
Cas No.	1640282-42-3
Smiles	Cc1cnc(cc1-n1c(C)cc(OCc2ncc(F)cc2F)c(Cl)c1=O)-c1ccnc(n1)C(C)(C)O

Storage & Solubility Information

Storage

store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (155.67 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.42 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.9458 mL	9.7291 mL	19.4583 mL	97.2914 mL
5 mM	0.3892 mL	1.9458 mL	3.8917 mL	19.4583 mL
10 mM	0.1946 mL	0.9729 mL	1.9458 mL	9.7291 mL
20 mM	0.0973 mL	0.4865 mL	0.9729 mL	4.8646 mL
50 mM	0.0389 mL	0.1946 mL	0.3892 mL	1.9458 mL
100 mM	0.0195 mL	0.0973 mL	0.1946 mL	0.9729 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc